Enhancing Mesenchymal Stem Cell Survival and Homing Capability to Improve Cell Engraftment Efficacy for Liver Diseases

Overview

Journal Stem Cell Res Ther

Publisher Biomed Central

Date 2023 Sep 4

PMID 37667383

Authors

Shaoxiong Yu

Saihua Yu

Haiyan Liu

Naishun Liao

Xiaolong Liu

Affiliations

Soon will be listed here.

Abstract

Although mesenchymal stem cell (MSC) transplantation provides an alternative strategy for end-stage liver disease (ESLD), further widespread application of MSC therapy is limited owing to low cell engraftment efficiency. Improving cell engraftment efficiency plays a critical role in enhancing MSC therapy for liver diseases. In this review, we summarize the current status and challenges of MSC transplantation for ESLD. We also outline the complicated cell-homing process and highlight how low cell engraftment efficiency is closely related to huge differences in extracellular conditions involved in MSC homing journeys ranging from constant, controlled conditions in vitro to variable and challenging conditions in vivo. Improving cell survival and homing capabilities enhances MSC engraftment efficacy. Therefore, we summarize the current strategies, including hypoxic priming, drug pretreatment, gene modification, and cytokine pretreatment, as well as splenectomy and local irradiation, used to improve MSC survival and homing capability, and enhance cell engraftment and therapeutic efficiency of MSC therapy. We hope that this review will provide new insights into enhancing the efficiency of MSC engraftment in liver diseases.

Citing Articles

Reduced glutathione enhances adipose tissue-derived mesenchymal stem cell engraftment efficiency for liver fibrosis by targeting TGFβ1/SMAD3/NOX4 pathway.

Yu S, Wang Y, Shi Y, Yu S, Zhao B, Liao N Bioeng Transl Med. 2025; 10(2):e10735.

PMID: 40060764 PMC: 11883125. DOI: 10.1002/btm2.10735.

Standardization to Characterize the Complexity of Vessel Network Using the Aortic Ring Model.

Wolint P, Hofmann S, von Atzigen J, Boni R, Miescher I, Giovanoli P Int J Mol Sci. 2025; 26(1.

PMID: 39796147 PMC: 11719671. DOI: 10.3390/ijms26010291.

Molecular Mechanisms of Fibrosis in Cholestatic Liver Diseases and Regenerative Medicine-Based Therapies.

Wang W, Lian H, Liang Y, Ye Y, Tam P, Chen Y Cells. 2024; 13(23).

PMID: 39682745 PMC: 11640075. DOI: 10.3390/cells13231997.

Current Status of Research on Nanomaterials Combined with Mesenchymal Stem Cells for the Treatment of Ischemic Stroke.

Xu Q, Gu L, Li Z, Gao L, Wei L, Shafiq Z Neuromolecular Med. 2024; 26(1):51.

PMID: 39644405 DOI: 10.1007/s12017-024-08819-9.

Enhancing the functionality of mesenchymal stem cells: An attractive treatment strategy for metabolic dysfunction-associated steatotic liver disease?.

Shan X, Zhao L World J Stem Cells. 2024; 16(10):854-859.

PMID: 39493827 PMC: 11525648. DOI: 10.4252/wjsc.v16.i10.854.

References

Asrani S, Devarbhavi H, Eaton J, Kamath P . Burden of liver diseases in the world. J Hepatol. 2018; 70(1):151-171. DOI: 10.1016/j.jhep.2018.09.014. View

Forbes S, Gupta S, Dhawan A . Cell therapy for liver disease: From liver transplantation to cell factory. J Hepatol. 2015; 62(1 Suppl):S157-69. DOI: 10.1016/j.jhep.2015.02.040. View

Yang X, Meng Y, Han Z, Ye F, Wei L, Zong C . Mesenchymal stem cell therapy for liver disease: full of chances and challenges. Cell Biosci. 2020; 10:123. PMC: 7590738. DOI: 10.1186/s13578-020-00480-6. View

Zhang L, Ma X, Fei Y, Han H, Xu J, Cheng L . Stem cell therapy in liver regeneration: Focus on mesenchymal stem cells and induced pluripotent stem cells. Pharmacol Ther. 2021; 232:108004. DOI: 10.1016/j.pharmthera.2021.108004. View

Hu X, Chen L, Wu H, Tang Y, Zheng Q, Wei X . Cell therapy in end-stage liver disease: replace and remodel. Stem Cell Res Ther. 2023; 14(1):141. PMC: 10210428. DOI: 10.1186/s13287-023-03370-z. View

Khan S, Mahgoub S, Fallatah N, Lalor P, Newsome P . Liver Disease and Cell Therapy: Advances Made and Remaining Challenges. Stem Cells. 2023; 41(8):739-761. PMC: 10809282. DOI: 10.1093/stmcls/sxad029. View

Yang X, Li Q, Liu W, Zong C, Wei L, Shi Y . Mesenchymal stromal cells in hepatic fibrosis/cirrhosis: from pathogenesis to treatment. Cell Mol Immunol. 2023; 20(6):583-599. PMC: 10229624. DOI: 10.1038/s41423-023-00983-5. View

Liu W, Song F, Ren L, Guo W, Wang T, Feng Y . The multiple functional roles of mesenchymal stem cells in participating in treating liver diseases. J Cell Mol Med. 2014; 19(3):511-20. PMC: 4369809. DOI: 10.1111/jcmm.12482. View

Kuo T, Hung S, Chuang C, Chen C, Shih Y, Fang S . Stem cell therapy for liver disease: parameters governing the success of using bone marrow mesenchymal stem cells. Gastroenterology. 2008; 134(7):2111-21, 2121.e1-3. PMC: 3086672. DOI: 10.1053/j.gastro.2008.03.015. View

10.

Liao N, Su L, Cao Y, Qiu L, Xie R, Peng F . Tracking Cell Viability for Adipose-Derived Mesenchymal Stem Cell-Based Therapy by Quantitative Fluorescence Imaging in the Second Near-Infrared Window. ACS Nano. 2022; 16(2):2889-2900. DOI: 10.1021/acsnano.1c09960. View

11.

de Cassia Noronha N, Mizukami A, Caliari-Oliveira C, Cominal J, Rocha J, Covas D . Priming approaches to improve the efficacy of mesenchymal stromal cell-based therapies. Stem Cell Res Ther. 2019; 10(1):131. PMC: 6498654. DOI: 10.1186/s13287-019-1224-y. View

12.

Keating A . Mesenchymal stromal cells: new directions. Cell Stem Cell. 2012; 10(6):709-716. DOI: 10.1016/j.stem.2012.05.015. View

13.

Ankrum J, Ong J, Karp J . Mesenchymal stem cells: immune evasive, not immune privileged. Nat Biotechnol. 2014; 32(3):252-60. PMC: 4320647. DOI: 10.1038/nbt.2816. View

14.

Gebler A, Zabel O, Seliger B . The immunomodulatory capacity of mesenchymal stem cells. Trends Mol Med. 2011; 18(2):128-34. DOI: 10.1016/j.molmed.2011.10.004. View

15.

Li Z, Zhou X, Han L, Shi M, Xiao H, Lin M . Human Umbilical Cord Blood-Derived Mesenchymal Stem Cell Transplantation for Patients with Decompensated Liver Cirrhosis. J Gastrointest Surg. 2023; 27(5):926-931. PMC: 10133084. DOI: 10.1007/s11605-022-05528-1. View

16.

Shi M, Li Y, Xu R, Meng F, Yu S, Fu J . Mesenchymal stem cell therapy in decompensated liver cirrhosis: a long-term follow-up analysis of the randomized controlled clinical trial. Hepatol Int. 2021; 15(6):1431-1441. PMC: 8651584. DOI: 10.1007/s12072-021-10199-2. View

17.

Lin B, Chen J, Qiu W, Wang K, Xie D, Chen X . Allogeneic bone marrow-derived mesenchymal stromal cells for hepatitis B virus-related acute-on-chronic liver failure: A randomized controlled trial. Hepatology. 2017; 66(1):209-219. DOI: 10.1002/hep.29189. View

18.

Mohamadnejad M, Alimoghaddam K, Bagheri M, Ashrafi M, Abdollahzadeh L, Akhlaghpoor S . Randomized placebo-controlled trial of mesenchymal stem cell transplantation in decompensated cirrhosis. Liver Int. 2013; 33(10):1490-6. DOI: 10.1111/liv.12228. View

19.

Kantarcioglu M, Demirci H, Avcu F, Karslioglu Y, Babayigit M, Karaman B . Efficacy of autologous mesenchymal stem cell transplantation in patients with liver cirrhosis. Turk J Gastroenterol. 2015; 26(3):244-50. DOI: 10.5152/tjg.2015.0074. View

20.

Ullah M, Liu D, Thakor A . Mesenchymal Stromal Cell Homing: Mechanisms and Strategies for Improvement. iScience. 2019; 15:421-438. PMC: 6529790. DOI: 10.1016/j.isci.2019.05.004. View